Opinion|Videos|February 25, 2025
Role of Patient History in Neurogenic Bladder Diagnosis
Author(s)Tamara Kaplan, MD
Panelist discusses how a detailed patient history is critical for neurological lesion localization, helping physicians map symptoms to specific anatomical regions. Key bladder-related history focuses on urinary urgency, frequency, retention, and incontinence patterns, as these symptoms often indicate specific spinal cord or brain lesion locations that affect autonomic function.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role does a detailed patient history play in localizing neurological lesions?
- What are the key questions neurologists should ask when taking a patient’s history about bladder symptoms?
Advertisement
Related to this article
Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.
Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in patients with ALS.
Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.
A new study reported that tremor and myoclonus affected nearly 7 in 10 patients with chronic inflammatory demyelinating polyneuropathy, with immunotherapy and beta-blockers showing potential benefit for symptom improvement.
Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.
In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.
Robert Bowser, PhD, chief scientific officer at Barrow Neurological Institute, recaps his ALS Nexus presentation on TDP-43 biology, the emerging therapeutic landscape, and how cryptic peptide biomarkers could reshape ALS clinical trial design.
KuangHua Guo, MD, PhD, sleep specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Exploring the Unmet Needs in CIDP
2
Topline Phase 2 ADDRESS-LC Data Show Subgroup Benefit for Bezisterim in Long COVID
3
Brain Network Changes Appear Decades Before Motor Symptoms in Huntington Disease
4
Previewing Advancements in Hypersomnia Diagnosis and Treatment
5